HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

AbstractPURPOSE:
There are few treatment options for patients with metastasized or inoperable endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present the results of treatment with a radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).
PATIENTS AND METHODS:
One hundred thirty-one patients with somatostatin receptor-positive tumors were treated with up to a cumulative dose of 600 to 800 mCi (22.2 to 29.6 GBq) of 177Lu-octreotate.
RESULTS:
One patient developed renal insufficiency, and another patient developed hepatorenal syndrome. Creatinine clearance did not change significantly in the other patients. WHO hematologic toxicity grade 3 or 4 occurred after less than 2% of the administrations. We observed complete remission in three patients (2%), partial remission in 32 patients (26%), minor response (tumor diameter decrease of 25% to 50%) in 24 patients (19%), stable disease (SD) in 44 patients (35%), and progressive disease (PD) in 22 patients (18%). Higher remission rates were positively correlated with high uptake on pretherapy somatostatin receptor imaging and a limited number of liver metastases, whereas PD was significantly more frequent in patients with a low performance score and extensive disease. Median time to progression in 103 patients who either had SD or tumor regression was more than 36 months.
CONCLUSION:
Treatment with 177Lu-octreotate results in tumor remission in a high percentage of patients with GEP tumors. Serious side effects are rare. The median time to progression compares favorably with chemotherapy. Results are better in patients with a limited tumor load. Therefore, early treatment, even in patients who have no PD, may be better.
AuthorsDik J Kwekkeboom, Jaap J Teunissen, Willem H Bakker, Peter P Kooij, Wouter W de Herder, Richard A Feelders, Casper H van Eijck, Jan-Paul Esser, Boen L Kam, Eric P Krenning
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 23 Issue 12 Pg. 2754-62 (Apr 20 2005) ISSN: 0732-183X [Print] United States
PMID15837990 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • (177lutetium-DOTA(O)Tyr3)octreotate
  • Organometallic Compounds
  • Receptors, Somatostatin
  • Octreotide
Topics
  • Adenoma, Islet Cell (drug therapy, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoid Tumor (drug therapy, pathology)
  • Disease Progression
  • Endocrine Gland Neoplasms (drug therapy, pathology)
  • Female
  • Humans
  • Liver Neoplasms (drug therapy, secondary)
  • Male
  • Middle Aged
  • Octreotide (analogs & derivatives)
  • Organometallic Compounds (adverse effects, pharmacokinetics, therapeutic use)
  • Pancreatic Neoplasms (drug therapy, pathology)
  • Receptors, Somatostatin
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: